Komada Kenichi, Ichimura Yasunori, Shimada Mami, Funato Masafumi, Do Hung Thai, LE Huy Xuan, Hoang Thanh Tien, Nguyen Trieu Bao, Huynh Mai Kim, Hoang Hang Thi Hai, Tran Nhu Anh Thi, LE Thieu Hoang, Ngo Quyet Thi, Miyano Shinsuke, Sugiyama Masaya, Mizoue Tetsuya, Hachiya Masahiko
National Center for Global Health and Medicine, Japan 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Pasteur Institute in Nha Trang, Vietnam 8-10 Tran Phu St., Xuong Huan Ward, Nha Trang, Khanh Hoa, Viet Nam.
J Virus Erad. 2022 Dec 10;8(4):100309. doi: 10.1016/j.jve.2022.100309. eCollection 2022 Dec.
Vietnam introduced a 3-dose hepatitis B (HBV) immunization program comprising 1 dose immediately after birth and 2 or 3 in infancy in the past 20 years, but the impact of the vaccine has not been systematically evaluated. Thus, we conducted this survey aiming to estimate the age-specific chronic HBV prevalence in the general population and to evaluate HBV immunization effectiveness.
Population-based, four-stage cluster sampling was used in the South Central Coast region of Vietnam. The point-of-care Determine rapid test was used to assess hepatitis B surface antigen (HBsAg) positivity.
A total of 2,075 samples were included in the study. HBsAg prevalence was significantly higher among adults aged 20-39 years than in the population aged 1-19 years (8.0% [95% confidence interval 5.0-12.0] vs. 2.0% [95% confidence interval 1.0-6.0], p<0.01). HBsAg prevalence decreased after implementation of the 3-dose vaccination schedule during infancy from 1997 to 2002, whereas the change in prevalence after implementation of the birth dosing was not significant. A slight increase in HBsAg prevalence was observed for the cohort born in 2011, 2012, and 2013, when there was a vaccine shortage and media reports of immunization resistance.
This is the first population-based assessment of the introduction of the HBV vaccine in Vietnam performed by estimating the HBsAg prevalence across a wide range of ages. The results showed that the HBV immunization policy effectively reduces HBsAg prevalence in general, although birth dosing of the vaccine and low immunization coverage should be carefully monitored.
在过去20年里,越南推行了一项3剂次乙肝(HBV)免疫规划,包括出生后立即接种1剂次,以及在婴儿期接种2剂次或3剂次,但该疫苗的影响尚未得到系统评估。因此,我们开展了这项调查,旨在估计普通人群中特定年龄的慢性HBV流行率,并评估HBV免疫效果。
在越南中南部沿海地区采用基于人群的四阶段整群抽样方法。使用即时检测的Determine快速检测法评估乙肝表面抗原(HBsAg)阳性情况。
本研究共纳入2075份样本。20-39岁成年人的HBsAg流行率显著高于1-19岁人群(8.0%[95%置信区间5.0-12.0]vs.2.0%[95%置信区间1.0-6.0],p<0.01)。1997年至2002年婴儿期实施3剂次疫苗接种计划后,HBsAg流行率下降,而出生时接种疫苗后流行率的变化不显著。在2011年、2012年和2013年出生的队列中,观察到HBsAg流行率略有上升,当时存在疫苗短缺以及关于免疫抵抗的媒体报道。
这是越南首次通过估计广泛年龄范围内的HBsAg流行率对HBV疫苗引入情况进行基于人群的评估。结果表明,HBV免疫政策总体上有效降低了HBsAg流行率,尽管应仔细监测疫苗的出生时接种情况和低免疫覆盖率。